In this interview, Dr. Patel discusses the curative potential of novel therapeutic agents, issues with tolerability, and improvements he expects in the next few years.
In an interview with MedPage Today, Dr. Gehlhausen, of the Yale School of Medicine, discussed the use of this diagnostic tool, describing the techniques that are available and important considerations.
Dr. Ng and Mr. Lopez discuss the diagnosis of this rare lymphoma manifestation in an interview with MedPage Today.
Dr. Ramalingam discusses the utility of prognostic indicators such as tumor grade, mutational status, and more in follicular lymphoma.
Utilizing data from the GALLIUM trial, investigators identified several risk factors for histological transformation of follicular lymphoma in a recent secondary analysis.
This retrospective analysis of patients with follicular lymphoma found that a Follicular Lymphoma International Prognostic Index low/intermediate score in the absence of histological transformation was associated with a good prognosis even for patients with early relapse.
Patients with FL who experience disease progression within 24 months of first-line therapy have poorer overall survival compared with those who do not have progression within 24 months.